Hjem
Øystein Fløttens bilde

Øystein Fløtten

Førsteamanuensis
  • E-postOystein.Flotten@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • 2020. Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. Acta Oncologica.
  • 2018. Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement. Anticancer Research. 871-876.
  • 2018. Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials. Acta Oncologica. 1574-1579.
  • 2018. A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer. European Journal of Clinical Nutrition. 1-8.
  • 2017. Muscle mass and association to quality of life in non-small cell lung cancer patients. Journal of Cachexia, Sarcopenia and Muscle. 759-767.
  • 2017. Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. e129-e136.
  • 2016. Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer. Lung Cancer. 9-14.
  • 2016. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Annals of Oncology. 1291-1298.
  • 2016. Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Annals of Oncology. 225-232.
  • 2016. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clinical Nutrition. 1386-1393.
  • 2016. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncologica. 591-597.
  • 2016. Oral versus intravenous vinorelbine in advanced NSCLC - a retrospective comparison. Cancer Treatment and Research Communications. 15-20.
  • 2016. Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer. Acta Oncologica. 1349-1354.
  • 2015. Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer. 85-91.
  • 2013. Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. British Journal of Cancer. 1467-1475.
  • 2012. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. British Journal of Cancer. 442-447.
  • 2012. A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Lung Cancer. 63-69.
  • 2010. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. European Journal of Cancer. 2225-2234.
  • 2009. A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer. 88-93.
Doktorgradsavhandling
  • 2019. Simplifying Treatment of Advanced Non-small Cell Lung Cancer. Regimen, Route of Administration, and Patients' Preferences .
Sammendrag/abstract
  • 2015. Survival of patients with N3 lymph node disease in a cohort with limited disease small-cell lung cancer receiving concurrent chemoradiotherapy. Journal of Thoracic Oncology. s744.
  • 2015. Reduction in tumor size after the first course of cisplatin/etoposide (PE) in limited disease small-cell lung cancer (LD SCLC). Journal of Clinical Oncology.
  • 2015. Associations between Comorbidity, Treatment Toxicity and Overall Survival in Limited Disease Small-Cell Lung Cancer (LD-SCLC). Journal of Thoracic Oncology. s744.
  • 2012. Randomized phase II trial comparing two schedules of thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC). Journal of Clinical Oncology. 1 sider.
  • 2011. Randomized Phase Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer: The MENZA Study. European Journal of Cancer. 640-640.
Poster
  • 2018. Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small- cell lung cancer.
  • 2015. Association between comorbidity, treatment toxicity and overall survival in limited disease small-cell lung cancer.
  • 2012. Phase II Trial Comparing Two Schedules of Thoracic Radiotherapy in Limited Disease Small-Cell Lung Cancer.
  • 2011. Randomized Phase Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer: The MENZA Study.
  • 2010. Phase III study comparing vinorelbine-gemcitabine with vinorelbine-carboplatin as first-line chemotherapy of advanced NSCLC: A Norwegian Lung Cancer Study Group trial.
  • 2010. Phase III study comparing vinorelbine-gemcitabine with vinorelbine-carboplatin as first-line chemotherapy of advanced NSCLC: A Norwegian Lung Cancer Study Group trial.
Vitenskapelig oversiktsartikkel/review
  • 2017. Implementation of lung cancer CT screening in the Nordic countries. 1249-1257.
Nettsider (opplysningsmateriale)
  • 2013. Nasjonal handlingsplan for lungekreft (for Helsedirektoratet, HD og Norwegian Lung Cancer Group, NLCG) - utredning og behandling (utredningskapittelet).

Se fullstendig oversikt over publikasjoner i CRIStin.